Colorado Drug Pricing Board Hits Back at Amgen Legal Challenge

A federal judge should decline to hear drugmaker Amgen Inc.‘s lawsuit against Colorado’s prescription drug pricing review board over a vote to pursue a price cap for Enbrel, the state attorney general’s office wrote Friday.

Amgen, which filed its lawsuit against the Colorado Prescription Drug Affordability Board in March, has failed to demonstrate standing or a claim upon which relief can be granted by the court, attorneys in the office of Colorado Attorney General Philip J. Weiser wrote in the state’s first official response to Amgen’s legal challenge.

Amgen argued in its complaint filed in the US District Court ...